Pfizer Inc. $PFE Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP reduced its position in Pfizer Inc. (NYSE:PFE - Free Report) by 37.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 845,257 shares of the biopharmaceutical company's stock after selling 510,530 shares during the period. Sarasin & Partners LLP's holdings in Pfizer were worth $20,354,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Evanson Financial LLC purchased a new position in shares of Pfizer during the 2nd quarter valued at approximately $284,000. Fermata Advisors LLC bought a new stake in shares of Pfizer in the second quarter worth $232,000. 180 Wealth Advisors LLC increased its stake in shares of Pfizer by 1.1% in the second quarter. 180 Wealth Advisors LLC now owns 47,953 shares of the biopharmaceutical company's stock worth $1,155,000 after buying an additional 506 shares during the last quarter. M.E. Allison & CO. Inc. raised its holdings in Pfizer by 5.3% in the second quarter. M.E. Allison & CO. Inc. now owns 41,742 shares of the biopharmaceutical company's stock valued at $1,005,000 after acquiring an additional 2,112 shares in the last quarter. Finally, Integral Investment Advisors Inc. boosted its stake in Pfizer by 7.5% during the 2nd quarter. Integral Investment Advisors Inc. now owns 10,438 shares of the biopharmaceutical company's stock valued at $251,000 after acquiring an additional 725 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 1.4%

NYSE:PFE opened at $26.18 on Friday. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75. The firm has a market capitalization of $149.24 billion, a P/E ratio of 34.45 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.94. The business has a 50 day simple moving average of $25.01 and a 200 day simple moving average of $26.16.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm's revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer's dividend payout ratio (DPR) is 226.32%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on PFE shares. CICC Research began coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an "outperform" rating and a $33.00 target price for the company. BMO Capital Markets lowered their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, July 13th. Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective on the stock in a research note on Tuesday, June 9th. Wolfe Research reaffirmed an "underperform" rating and set a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. Finally, HSBC lowered Pfizer from a "buy" rating to a "hold" rating and decreased their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $28.50.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 earnings beat and guidance increase: Pfizer reported adjusted earnings of $0.77 per share versus the $0.68 consensus estimate, while revenue of $15.03 billion exceeded expectations of $14.40 billion. Management raised the low end of its 2026 revenue outlook, supported by Eliquis and other non-COVID products. Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
• Positive Sentiment: Cost savings and pipeline support: Pfizer expanded its cost-reduction target, providing a potential lift to future margins and cash flow. Analysts also highlighted continued growth in newer products and a broader R&D pipeline as offsets to declining COVID revenue. PFE Q2 Deep Dive: New Products Offset COVID Decline, R&D Pipeline Expands
• Positive Sentiment: Clinical catalysts: Pfizer reported positive Phase 3 data for LITFULO in vitiligo and announced progress in a pediatric COVID booster study. It also completed a Phase 1 study of PF-07328948, adding incremental support to its longer-term pipeline narrative. Pfizer Reports Positive Phase 3 LITFULO Data in Vitiligo
• Neutral Sentiment: Analyst view remains mixed: Some coverage describes Pfizer as attractive for income investors because of its high dividend yield and potential undervaluation, while RBC Capital maintained a Hold rating. Investors remain focused on execution and the sustainability of the recovery. RBC Capital Remains a Hold on Pfizer
• Negative Sentiment: COVID and pipeline risks persist: COVID pill revenue reportedly fell 95%, and setbacks surrounding Pfizer’s obesity program, along with upcoming patent expirations, continue to raise concerns about long-term growth. These risks explain why the market’s response remains measured despite the earnings beat. Pfizer Covid Pill Revenue Plunges 95%

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source